The Client |
|
Our client is a Singapore-headquartered medical & life sciences company specializing in the research, development, and commercialization of advanced health supplements and medical foods. With over 15 years of proprietary scientific research, the company has developed a breakthrough ingredient—Efila™, a liquid compound derived from patented fungal strains—used across its line of products to support immune function and manage chronic conditions like Type 2 diabetes.
With a global supply chain and advanced manufacturing partnerships across Asia, the company is gearing up for international expansion with strategic distribution interest from major players in the US and China, including Sinopharm and Nature Made. Its operations are backed by a seasoned R&D team comprising international biopharmaceutical experts, and it is poised to position Singapore as a hub for high-tech health product manufacturing.
With a global supply chain and advanced manufacturing partnerships across Asia, the company is gearing up for international expansion with strategic distribution interest from major players in the US and China, including Sinopharm and Nature Made. Its operations are backed by a seasoned R&D team comprising international biopharmaceutical experts, and it is poised to position Singapore as a hub for high-tech health product manufacturing.
How RIC Helped |
|
Grant Secured:
RIC supported the client in securing the Enterprise Development Grant (EDG) under the Innovation & Productivity – New Product Development category. The project received an approval of close to S$80,000 in grant support, covering up to 80% of eligible clinical validation costs.
Scope of Our Consulting and Advisory:
RIC worked closely with the client to scope and articulate a highly technical and commercially impactful project focused on the clinical validation of a next-generation medical food, DM Friends™, intended for diabetic patients. RIC’s work included:
RIC supported the client in securing the Enterprise Development Grant (EDG) under the Innovation & Productivity – New Product Development category. The project received an approval of close to S$80,000 in grant support, covering up to 80% of eligible clinical validation costs.
Scope of Our Consulting and Advisory:
RIC worked closely with the client to scope and articulate a highly technical and commercially impactful project focused on the clinical validation of a next-generation medical food, DM Friends™, intended for diabetic patients. RIC’s work included:
- Deep project articulation in areas such as disease pathophysiology, beta cell regeneration, and diabetes biomarkers to highlight the scientific value of the product.
- Vendor selection and cost planning, including due diligence on CRO partners and securing a suitable partner in Temasek Polytechnic, with clearly defined scopes, milestones, and deliverables.
- Comprehensive impact analysis, including projections for global market expansion, new job creation, and the future setup of a Singapore-based high-tech manufacturing facility.
- Business impact forecasting, showing exponential revenue potential (from ~S$1.6M in 2022 to over S$89M by 2025) and plans to add PMET roles in marketing, BD, and distribution.
- Full submission and compliance support on the Business Grant Portal (BGP), managing all backend submission processes including qualifying cost itemization, milestone inputs, and grant acceptance workflows.
Outcomes |
|
The project, currently in execution, is expected to deliver:
RIC worked hand-in-hand with the client throughout the process—from concept to grant approval to execution support. Our technical understanding of AI and cybersecurity, combined with fluency in innovation grants, was key in framing this complex project in a way that secured government support and set the client on a clear path to commercialization and expansion.
This case underscores RIC’s strengths in delivering outcomes for deep-tech innovators in emerging fields. With an unique ability to scope, articulate, and support high-risk, high-reward projects, RIC is the consultancy of choice for companies at the frontier of AI, cybersecurity, and innovation.
- Two novel AI cybersecurity products: ModelScan (static analysis tool for AI apps and models) and ModelDefender (prompt filtering and anomaly detection engine).
- Market-ready tools for deployment in enterprise LLM applications, with significant implications for banks, governments, and healthcare providers developing their own generative AI models.
- Over S$450,000 in annual productivity savings for typical enterprise clients, due to reduced DevSecOps man-hours across vulnerability scanning, penetration testing, and access control.
- Strategic market entry into Japan, positioning the company to gain up to 2.6% market share in the LLM cybersecurity segment within five years.
- Enhanced internal capabilities, including upskilling in regulatory compliance, anomaly detection, and secure software lifecycle processes.
- Global thought leadership, as demonstrated by multiple research publications authored by the company’s team on adversarial AI and LLM jailbreak vulnerabilities.
RIC worked hand-in-hand with the client throughout the process—from concept to grant approval to execution support. Our technical understanding of AI and cybersecurity, combined with fluency in innovation grants, was key in framing this complex project in a way that secured government support and set the client on a clear path to commercialization and expansion.
This case underscores RIC’s strengths in delivering outcomes for deep-tech innovators in emerging fields. With an unique ability to scope, articulate, and support high-risk, high-reward projects, RIC is the consultancy of choice for companies at the frontier of AI, cybersecurity, and innovation.